In April, we added 110 citations in DIDB, including 51 in vitro (with 22 articles published in June 2025) and 59 in vivo articles (with 28 articles published in June 2025).
3 NDA/BLAs approved in May 2025, including avutometinib and defactinib (AVMAPKI FAKZYNJA CO-PACK), acoltremon (TRYPTYR), and telisotuzumab vedotin (EMRELIS) were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.